Forest's Ceftaroline Sets Standard For Skin Infection Drugs Under New FDA Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-Infective Drugs Advisory Committee unanimously endorses the beta lactam cephalosporin for complicated skin and skin structure infections, saying FDA's sensitivity analyses using new endpoints and population criteria bolstered the drug.
You may also be interested in...
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
The new endpoint proposed in FDA’s recent acute bacterial skin and skin structure infections guidance – cessation of lesion spread – needs further refinement to be a reliable assessment of antibiotic efficacy, according to members of the agency’s Anti-Infective Drugs Advisory Committee.
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
The new endpoint proposed in FDA’s recent acute bacterial skin and skin structure infections guidance – cessation of lesion spread – needs further refinement to be a reliable assessment of antibiotic efficacy, according to members of the agency’s Anti-Infective Drugs Advisory Committee.
Ceftaroline Label Needs Clarity On Lack Of MRSA Data For CABP, Panel Says
Labeling for Forest Laboratories' ceftaroline fosamil must specify that the antibiotic has not been clinically evaluated to treat methicillin-resistant Staphylococcus aureus in patients with community-acquired bacterial pneumonia, members of the Anti-Infective Drugs Advisory Committee told FDA Sept 7.